Alzeca Biosciences said today that it raised $11 million in a Series A round to fund the development of its MRI imaging agent designed for the early diagnosis of Alzheimer’s disease and other neurodegenerative disorders. The company touts its ADx nanoparticle as the first MRI contrast agent to target amyloid – a brain protein linked […]
